Outputs (34)

Differential benefit of adjuvant everolimus according to endocrine therapy backbone in the randomized UNIRAD trial. (2025)
Journal Article
Saint-Ghislain, M., Chabaud, S., Dalenc, F., Allouache, D., Cameron, D., Martinez, M., Grenier, J., Barthelemy, P., Brunt, M., Kaluzinski, L., Mailliez, A., Legouffe, E., Hardy-Bessard, A.-C., Giacchetti, S., Mouret-Reynier, M.-A., Canon, J.-L., Bliss, J., Lemonnier, J., Andre, F., Bachelot, T., & Cottu, P. (2025). Differential benefit of adjuvant everolimus according to endocrine therapy backbone in the randomized UNIRAD trial. ESMO Open, 10(5), Article 105050. https://doi.org/10.1016/j.esmoop.2025.105050

The randomized, double-blind UNIRAD trial evaluating the addition of 2 years of everolimus to endocrine therapy in patients with high-risk, early luminal breast cancer failed to demonstrate a benefit. We report the subgroup analyses. We randomly assi... Read More about Differential benefit of adjuvant everolimus according to endocrine therapy backbone in the randomized UNIRAD trial..

Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial. (2023)
Journal Article
Velikova, G., Morden, J. P., Haviland, J. S., Emery, C., Barrett-Lee, P., Earl, H., Bloomfield, D., Brunt, A. M., Canney, P., Coleman, R., Verrill, M., Wardley, A., Bertelli, G., Ellis, P., Stein, R., Bliss, J. M., & Cameron, D. (in press). Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial. Lancet Oncology, S1470-2045(23)00460-6. https://doi.org/10.1016/S1470-2045%2823%2900460-6

Adjuvant chemotherapy for patients with early breast cancer improves outcomes but its toxicity affects patients' quality of life (QOL). The UK TACT2 trial investigated whether accelerated epirubicin improves time to recurrence and if oral capecitabin... Read More about Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial..

Dose-escalated simultaneous integrated boost radiotherapy in early breast cancer (IMPORT HIGH): a multicentre, phase 3, non-inferiority, open-label, randomised controlled trial. (2023)
Journal Article
Coles, C. E., Haviland, J. S., Kirby, A. M., Griffin, C. L., Sydenham, M. A., Titley, J. C., Bhattacharya, I., Brunt, A. M., Chan, H. Y. C., Donovan, E. M., Eaton, D. J., Emson, M., Hopwood, P., Jefford, M. L., Lightowlers, S. V., Sawyer, E. J., Syndikus, I., Tsang, Y. M., Twyman, N. I., Yarnold, J. R., & Bliss, J. M. (in press). Dose-escalated simultaneous integrated boost radiotherapy in early breast cancer (IMPORT HIGH): a multicentre, phase 3, non-inferiority, open-label, randomised controlled trial. Lancet, 401(10394), 2124-2137. https://doi.org/10.1016/S0140-6736%2823%2900619-0

A tumour-bed boost delivered after whole-breast radiotherapy increases local cancer-control rates but requires more patient visits and can increase breast hardness. IMPORT HIGH tested simultaneous integrated boost against sequential boost with the ai... Read More about Dose-escalated simultaneous integrated boost radiotherapy in early breast cancer (IMPORT HIGH): a multicentre, phase 3, non-inferiority, open-label, randomised controlled trial..

Hypofractionation: The standard for external beam breast irradiation (2023)
Journal Article
Brunt, A. M., & Haviland, J. S. (2023). Hypofractionation: The standard for external beam breast irradiation. Breast, 69, 410-416. https://doi.org/10.1016/j.breast.2023.04.006

This overview provides the historical perspective of external beam breast hypofractionation over the last 50 years. It highlights the serious harm suffered by patients with breast cancer in the 1970's and 1980's because of new hypofractionation regim... Read More about Hypofractionation: The standard for external beam breast irradiation.

Hypofractionation: The standard for external beam breast irradiation (2023)
Journal Article
Brunt, A. M., & Haviland, J. S. (2023). Hypofractionation: The standard for external beam breast irradiation. Breast, 69, 410 - 416. https://doi.org/10.1016/j.breast.2023.04.006

This overview provides the historical perspective of external beam breast hypofractionation over the last 50 years. It highlights the serious harm suffered by patients with breast cancer in the 1970's and 1980's because of new hypofractionation regim... Read More about Hypofractionation: The standard for external beam breast irradiation.

Data from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results (2023)
Data
Bundred, N., Porta, N., Brunt, A. M., Cramer, A., Hanby, A., Shaaban, A. M., Rakha, E. A., Armstrong, A., Cutress, R. I., Dodwell, D., Emson, M. A., Evans, A., Hartup, S. M., Horgan, K., Miller, S. E., McIntosh, S. A., Morden, J. P., Naik, J., Narayanan, S., Ooi, J., …Bliss, J. M. (2023). Data from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results. [Data]. https://doi.org/10.1158/1078-0432.c.6532623.v1

Purpose:
EPHOS-B aimed to determine whether perioperative anti-HER2 therapy inhibited proliferation and/or increased apoptosis in HER2-positive breast cancer.

Patients and Methods:
This randomized phase II, two-part, multicenter trial included n... Read More about Data from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results.

Detailed Sub-study Analysis of the SECRAB Trial: Quality of Life, Cosmesis and Chemotherapy Dose Intensity (2023)
Journal Article
Fernando, I., Lax, S., Bowden, S., Ahmed, I., Steven, J., Churn, M., Brunt, A., Agrawal, R., Canney, P., Stevens, A., & Rea, D. (2023). Detailed Sub-study Analysis of the SECRAB Trial: Quality of Life, Cosmesis and Chemotherapy Dose Intensity. Clinical Oncology, 35(6), 397-407. https://doi.org/10.1016/j.clon.2023.03.007

Aims
SECRAB was a prospective, open-label, multicentre, randomised phase III trial comparing synchronous to sequential chemoradiotherapy (CRT). Conducted in 48 UK centres, it recruited 2297 patients (1150 synchronous and 1146 sequential) between 2 J... Read More about Detailed Sub-study Analysis of the SECRAB Trial: Quality of Life, Cosmesis and Chemotherapy Dose Intensity.

One versus three weeks hypofractionated whole breast radiotherapy for early breast cancer treatment: the FAST-Forward phase III RCT (2023)
Report
Brunt, A., Haviland, J. S., Wheatley, D. A., Sydenham, M. A., Bloomfield, D. J., Chan, C., Cleator, S., Coles, C. E., Donovan, E., Fleming, H., Glynn, D., Goodman, A., Griffin, S., Hopwood, P., Kirby, A. M., Kirwan, C. C., Nabi, Z., Patel, J., Sawyer, E., Somaiah, N., …Bliss, J. M. (2023). One versus three weeks hypofractionated whole breast radiotherapy for early breast cancer treatment: the FAST-Forward phase III RCT

FAST-Forward aimed to identify a 5-fraction schedule of adjuvant radiotherapy delivered in 1 week that was non-inferior in terms of local cancer control and as safe as the standard 15-fraction regimen after primary surgery for early breast cancer. Pu... Read More about One versus three weeks hypofractionated whole breast radiotherapy for early breast cancer treatment: the FAST-Forward phase III RCT.

Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II study. (2023)
Journal Article
Oswald, A., Symeonides, S., Wheatley, D., Chan, S., Brunt, A., McAdam, K., Schmid, P., Waters, S., Poole, C., Twelves, C., Perren, T., Bartlett, J., Piper, T., Chisholm, E., Welsh, M., Hill, R., Hopcroft, L., Barrett-Lee, P., & Cameron, D. (2023). Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II study. Breast Cancer Research and Treatment, 199, https://doi.org/10.1007/s10549-023-06873-8

PURPOSE: The development of oestrogen resistance is a major challenge in managing hormone-sensitive metastatic breast cancer. Saracatinib (AZD0530), an oral Src kinase inhibitor, prevents oestrogen resistance in animal models and reduces osteoclast a... Read More about Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II study..

Cost-effectiveness of 5 fraction and partial breast radiotherapy for early breast cancer in the UK: model-based multi-trial analysis. (2022)
Journal Article
Glynn, D., Bliss, J., Brunt, A. M., Coles, C. E., Wheatley, D., Haviland, J. S., Kirby, A. M., Longo, F., Faria, R., Yarnold, J. R., & Griffin, S. (2022). Cost-effectiveness of 5 fraction and partial breast radiotherapy for early breast cancer in the UK: model-based multi-trial analysis. Breast Cancer Research and Treatment, 197, 405-416. https://doi.org/10.1007/s10549-022-06802-1

PURPOSE: We estimated the cost-effectiveness of 4 radiotherapy modalities to treat early breast cancer in the UK. In a subgroup of patients eligible for all modalities, we compared whole-breast (WB) and partial breast (PB) radiotherapy delivered in e... Read More about Cost-effectiveness of 5 fraction and partial breast radiotherapy for early breast cancer in the UK: model-based multi-trial analysis..